Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

NextCure, Inc. - Common Stock (NQ:NXTC)

10.93 -0.77 (-6.60%)
Streaming Delayed Price Updated: 2:41 PM EDT, Apr 21, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about NextCure, Inc. - Common Stock

< Previous 1 2 3 Next >
News headline image
NextCure and Simcere’s SIM0505 (CDH6 ADC) Phase 1 Data to be Presented at ASCO 2026
Poster to be presented at the American Society for Clinical Oncology on Monday, June 1, 2026 
From NextCure
Via GlobeNewswire
News headline image
NextCure Receives Fast Track Designation for SIM0505 (CDH6 ADC) in Ovarian Cancer
From NextCure
Via GlobeNewswire
News headline image
NextCure and Simcere’s SIM0505 (CDH6 ADC) Abstract Accepted for ASCO 2026
The American Society for Clinical Oncology to be held in Chicago May 29 – June 2, 2026 
From NextCure
Via GlobeNewswire
News headline image
NextCure Provides Business Update and Reports Full Year 2025 Financial Results
From NextCure
Via GlobeNewswire
News headline image
NextCure Provides Business Update
From NextCure
Via GlobeNewswire
News headline image
NextCure to Present at the Piper Sandler 37th Annual Healthcare Conference
From NextCure
Via GlobeNewswire
News headline image
NextCure Announces Closing of $21.5 Million PIPE Financing in Advance of First Half 2026 Phase 1 POC Data Readouts
From NextCure
Via GlobeNewswire
News headline image
NextCure Announces $21.5 Million Private Placement of Common Stock Priced at the Market Under Nasdaq Rules
From NextCure
Via GlobeNewswire
News headline image
NextCure Provides Business Update and Reports Third Quarter 2025 Financial Results
From NextCure
Via GlobeNewswire
News headline image
NextCure and Simcere Zaiming Announce Expansion of Ongoing Phase 1 Trial of SIM0505 (CDH6 ADC) into the United States
From NextCure
Via GlobeNewswire
News headline image
NextCure to Present at the H.C. Wainwright 27th Annual Global Investment Conference
From NextCure
Via GlobeNewswire
News headline image
NextCure Provides Business Update and Reports Second Quarter 2025 Financial Results
From NextCure
Via GlobeNewswire
News headline image
Preclinical Data Demonstrate Anti-Siglec-15 Treatment Improves Bone Microarchitecture and Reduces Fracture Incidence in Mice with Moderate-to-Severe Osteogenesis Imperfecta
From NextCure
Via GlobeNewswire
News headline image
NextCure and Simcere Zaiming Announce Strategic Partnership for a Novel Antibody-Drug Conjugate Targeting CDH6
From NextCure
Via GlobeNewswire
News headline image
NextCure and LigaChemBio to Present Trial in Progress Poster for LNCB74, a B7-H4 Targeted Antibody-Drug Conjugate, as Monotherapy in Participants with Advanced Solid Tumors at ASCO 2025
From NextCure
Via GlobeNewswire
News headline image
NextCure Provides Business Update and Reports First Quarter 2025 Financial Results
From NextCure
Via GlobeNewswire
News headline image
NextCure to Present at 24th Annual Needham Virtual Healthcare Conference
From NextCure
Via GlobeNewswire
News headline image
NextCure Provides Business Update and Reports Full Year 2024 Financial Results
From NextCure
Via GlobeNewswire
News headline image
NextCure Announces First Patient Dosed in the Phase 1 Study of LNCB74 (B7-H4 ADC) as Therapeutic for Treating Multiple Cancers
From NextCure
Via GlobeNewswire
News headline image
NextCure Announces Acceptance of IND Application for LNCB74
LNCB74 is a B7-H4-targeting antibody-drug conjugate being developed for multiple cancers in partnership with LigaChem Biosciences 
From NextCure
Via GlobeNewswire
News headline image
NextCure to Participate in the 36th Annual Piper Sandler Healthcare Conference
From NextCure
Via GlobeNewswire
News headline image
Preclinical Data Demonstrates Anti-Siglec-15 Treatment Enhanced Generation of Quality Bone with Better Mechanical Properties in Mice with Moderate-to-Severe Osteogenesis Imperfecta
From NextCure
Via GlobeNewswire
News headline image
NextCure Provides Business Update and Reports Third Quarter 2024 Financial Results
From NextCure
Via GlobeNewswire
News headline image
NextCure Reports Preclinical Data for LNCB74 and Additional Clinical Biomarker Data for NC410 Combo at Society for Immunotherapy of Cancer Annual Meeting
From NextCure
Via GlobeNewswire
News headline image
NextCure to Give Two Presentations at Society for Immunotherapy of Cancer Annual Meeting
From NextCure
Via GlobeNewswire
News headline image
NextCure Presented Results of the Phase 1b Study of NC410 in Combination with Pembrolizumab at ESMO 2024
From NextCure
Via GlobeNewswire
News headline image
NextCure Provides Business Update and Reports Second Quarter 2024 Financial Results
From NextCure
Via GlobeNewswire
News headline image
NextCure to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
From NextCure
Via GlobeNewswire
News headline image
NextCure Presents Phase 1b Data on NC410 and Pembrolizumab Combination at ASCO 2024
From NextCure
Via GlobeNewswire
News headline image
NextCure Provides Business Update and Reports First Quarter 2024 Financial Results
From NextCure
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.